newsfilter
← Latest News
GlobeNewswire·

IMUNON to Present at the Life Sciences Investor Forum on June 25th

  • IMUNON, Inc. (NASDAQ: IMNN) announced CEO Stacy Lindborg will present at the Life Sciences Investor Forum on June 25, 2026, at 12:00 p.m. ET.
  • The live online event includes real-time investor Q&A, with registration & 1x1 meetings available via provided links.
  • An archived webcast will be accessible after the event on the IMUNON website under the News & Investors tab.
  • IMUNON focuses on non-viral DNA technology modalities: TheraPlas for solid tumors & PlaCCine for viral antigens.
  • Lead program IMNN-001 is a DNA-based immunotherapy for advanced ovarian cancer currently in Phase 3 (OVATION 3) following Phase 2 (OVATION 2).
  • The company completed dosing in a first-in-human study for its COVID-19 booster vaccine, IMNN-101.
  • IMUNON includes standard forward-looking statements regarding clinical trial timing, product potential, & regulatory risks.
  • Media inquiries are directed to Jenna Urban of CG life & investor inquiries to Peter Vozzo of ICR Healthcare.